ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/LAG-3 Bispecific Antibody AK129

Also written as “Drug: AK129 Drug:oxaliplatin Drug:capecitabine”, “Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine” and “AK129 IV infusion”.

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Hodgkin Disease, led by Akeso.

Drug pageAnti-PD-1/LAG-3 Bispecific Antibody AK129: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 4, 20244 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso42 open or runningphase 2since Sep 4, 2024Nov 17, 2022Dec 2026phase 2 · NCT06943820

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2022First study: phase 1 study in Advanced Malignant Tumors(Stage IA-IB)First studyNCT05645276 · 57 enrolled · China
  2. Sep 4, 20242 phase 2 studiesNCT06586294, NCT06642792
  3. Apr 6, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06943820 · 230 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06943820
  2. Nov 2027Primary completion: phase 2 study in Classic Hodgkin LymphomaNCT06642792

TargetBeta

LAG3 →PDCD1 →read by rule
“A humanized, immunoglobulin G1 (IgG1) bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; programmed death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
TQB2252Sino Biopharmaceuticalphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06943820Squamous Cell Carcinoma of Head and Neck · China2RecruitingDec 2026230
NCT06642792Classic Hodgkin Lymphoma · China2RecruitingNov 2027280
NCT06586294Gastric Adenocarcinoma · China2CompletedApr 20, 202635
NCT05645276Advanced Malignant Tumors(Stage IA-IB) · China1CompletedJun 9, 202657

How it is read

Names in the registry

  • “Drug: AK129 Drug:oxaliplatin Drug:capecitabine”, 1 entry
  • “Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine”, 1 entry
  • “AK129 IV infusion”, 1 entry
  • “AK129(dose 1)”, 1 entry
  • “AK129(dose 2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.